Pregabalin for the treatment of fibromyalgia

Bibliography

• McNalley JD, Matheson DA, Bakowshy VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006;27:9-16
   PubMedGoogle Scholar
• McBeth J, Mulvey MR. Fibromyalgia: mechanisms and potential impact of the ACR2010 classification criteria. Nat Rev Rheumatol 2012;8:108-16
   PubMed Web of Science ®Google Scholar
• Fitzcharles M-A, Yunus MB. The clinical concept of fibromyalgia as a changing paradigm in the past 20 years. Pain Res Treat 2012;2012:8
   Google Scholar
• White KP, Harth M. Classification, epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-9
   PubMedGoogle Scholar
• Wolfe F, Smythe HA, Muhammad B, The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles M-A, The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
   PubMed Web of Science ®Google Scholar
• McCarberg B, Barkin RL, Wright JA, Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther 2003;10:176-92
   PubMedGoogle Scholar
• Smith HS, Harris R, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 2011;14:E217-45
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007;11:343-51
   PubMedGoogle Scholar
• Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
   PubMed Web of Science ®Google Scholar
• Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rhematol 2011;25:285-97
   PubMed Web of Science ®Google Scholar
• Li Z, Taylor CP, Weber M, Pregabalin is a potent and selective ligand for (2)-1 and (2)-2 calcium channel subunits. Eur J Pharmacol 2011;667:80-90
   PubMed Web of Science ®Google Scholar
• Shoji S, Suzuki M, Tomono Y, Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol 2011;72:63-76
   PubMed Web of Science ®Google Scholar
• Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther 2010;17:418-39
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Clin Pharmacol 2003;43:277-83
   Google Scholar
• Crofford LJ, Rowbotham M, Mease PJ, Pregablin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;5:502-14
   Google Scholar
• Pauer L, Winkelmann A, Arsenault P, A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-2
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
   PubMed Web of Science ®Google Scholar
• Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin – a meta-analysis of randomized controlled trials. Pain 2009;145:69-81
   PubMed Web of Science ®Google Scholar
• Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-21
   PubMed Web of Science ®Google Scholar
• Tzellos TG, Toulis KA, Goulis DG, Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 2010;35:639-56
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rhematology (Oxford) 2010a;49:706-15
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, Moore RA, Pregabalin in fibromyalgia – responder analysis from individual patient data. BMC Musculoskelet Disord 2010b;11:150
   PubMed Web of Science ®Google Scholar
• Choy E, Marshall D, Gabriel ZL, A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011;41:335-45
   PubMed Web of Science ®Google Scholar
• Siler AC, Gardner H, Yanit K, Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain 2011;12:407-15
   PubMed Web of Science ®Google Scholar
• Sackett DL, Straus SE, Richardson WS, Evidence-based medicine: how to practice and teach EBM. JAMA 2000;284:2382-3
   Web of Science ®Google Scholar
• Roth T, Lankford DA, Bhadra P, Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005;70(144):43633-5
   PubMedGoogle Scholar
• Vaishnavi SN, Nemeroff CB, Plott SJ, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2
   PubMed Web of Science ®Google Scholar
• Farmer MV, Trugman JM, Wang Y, Gendreau RM. Effect of adding milnacipran to pregabalin for managing fibromyalgia: a randomized, open-label, controlled study [abstract]. Arthritis Rheum 2010;62(Suppl 10):648
   Google Scholar
• Busch AJ, Schachter CL, Overend TJ, Exercise for fibromyalgia: a systematic review. J Rheumatol 2008;35:1130-44
   PubMed Web of Science ®Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar